Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
5h agoPfizer Inc. wins early U.S. antitrust clearance for $7.3 bn Metsera Inc. deal
Pfizer has received early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, ahead of schedule, removing a major regulatory hurdle. Metsera’s shareholders are due to vote on the deal next month. Meanwhile, rivals say they have superior offers in the obesity-drug market. The clearance allows Pfizer to move ahead without further antitrust review under the Hart-Scott-Rodino Act. The deal positions Pfizer to enter the $150 bn obesity prescription drug market as its COVID-era revenues decline.
positive
5h agoPfizer Inc. wins early U.S. antitrust clearance for $7.3 bn Metsera Inc. deal
Pfizer has received early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, ahead of schedule, removing a major regulatory hurdle. Metsera’s shareholders are due to vote on the deal next month. Meanwhile, rivals say they have superior offers in the obesity-drug market. The clearance allows Pfizer to move ahead without further antitrust review under the Hart-Scott-Rodino Act. The deal positions Pfizer to enter the $150 bn obesity prescription drug market as its COVID-era revenues decline.
Breaking
positive
Pfizer Inc. wins early U.S. antitrust clearance for $7.3 bn Metsera Inc. deal
about 5 hours ago
1 min read
80 words
Pfizer secures early antitrust approval to acquire Metsera, accelerating its entry into the obesity-drug market.
Pfizer has received early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, ahead of schedule, removing a major regulatory hurdle. Metsera’s shareholders are due to vote on the deal next month. Meanwhile, rivals say they have superior offers in the obesity-drug market. The clearance allows Pfizer to move ahead without further antitrust review under the Hart-Scott-Rodino Act. The deal positions Pfizer to enter the $150 bn obesity prescription drug market as its COVID-era revenues decline.
Pfizer has received early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, ahead of schedule, removing a major regulatory hurdle. Metsera’s shareholders are due to vote on the deal next month. Meanwhile, rivals say they have superior offers in the obesity-drug market. The clearance allows Pfizer to move ahead without further antitrust review under the Hart-Scott-Rodino Act. The deal positions Pfizer to enter the $150 bn obesity prescription drug market as its COVID-era revenues decline.
Tags:
stocks
pharma
stocks
pharma
mergers
global
Oct 31, 2025 • 21:39 IST